Rho GAP inhibitors are a class of chemical compounds designed to target and inhibit the function of Rho GTPase-activating proteins (Rho GAPs). Rho GAPs are crucial regulators of the Rho family of GTPases, a group of proteins that act as molecular switches to control various cellular processes, such as cytoskeletal organization, cell migration, cell division, and intracellular signaling. Rho GTPases cycle between an active, GTP-bound state and an inactive, GDP-bound state. Rho GAPs facilitate the inactivation of Rho GTPases by accelerating the hydrolysis of GTP to GDP, thus turning off the signaling pathways regulated by Rho GTPases. Inhibitors of Rho GAPs work by blocking this function, preventing the inactivation of Rho GTPases and allowing them to remain in their active, GTP-bound state for longer durations. This prolonged activation can lead to enhanced Rho GTPase signaling in various cellular contexts.
The inhibition of Rho GAPs has significant consequences for cellular processes that depend on the tightly regulated cycling of Rho GTPases. By preventing the deactivation of Rho GTPases, Rho GAP inhibitors can affect the dynamics of the actin cytoskeleton, leading to alterations in cell shape, motility, adhesion, and division. These inhibitors allow researchers to study the precise role of Rho GAPs in cellular signaling networks and how their regulation of Rho GTPases impacts physiological and developmental processes. Additionally, Rho GAP inhibitors provide insights into the broader regulatory mechanisms that control the balance of GTPase activation and inactivation in cells. By modulating the activity of Rho GTPases, these inhibitors help to uncover the intricate pathways that govern cellular responses to environmental stimuli and intracellular cues, as well as the coordination of cytoskeletal structures necessary for processes like migration, polarity, and cell proliferation. The study of Rho GAP inhibitors thus advances the understanding of the molecular mechanisms underlying Rho GTPase signaling and its role in maintaining cellular function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, may lead to increased acetylation around the Rho GAP gene, resulting in transcriptional repression and decreased Rho GAP expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could induce hypomethylation of CpG islands within the Rho GAP gene promoter, thereby silencing its transcription and reducing Rho GAP expression. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
RG 108 can block DNA methyltransferases, potentially leading to the hypomethylation of the Rho GAP gene promoter, causing transcriptional silencing and lower Rho GAP expression. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 directly inhibits ROCK, which could create a negative feedback loop that reduces the transcription and subsequent expression of Rho GAP. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 specifically inhibits MEK1/2, potentially leading to decreased activation of downstream transcription factors that are crucial for Rho GAP gene transcription, thus reducing its expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002, by inhibiting PI3K, could decrease AKT phosphorylation and activation, which may be necessary for the transcriptional activation of the Rho GAP gene, leading to its decreased expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, possibly leading to reduced transcription factor activity for genes including Rho GAP, resulting in a decrease in Rho GAP expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 selectively inhibits p38 MAPK, potentially leading to decreased phosphorylation of transcription factors involved in Rho GAP gene expression, thereby reducing its expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK, which could decrease ERK pathway signaling, resulting in downregulation of transcriptional activators of the Rho GAP gene, and consequently, its decreased expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin acts as a PI3K inhibitor, potentially leading to a reduction in AKT-mediated signaling, which might be required for the optimal expression of Rho GAP, thus decreasing its levels. | ||||||